China Universal Asset Management Co. Ltd. Buys 28,038 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

China Universal Asset Management Co. Ltd. raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 53.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,943 shares of the company’s stock after purchasing an additional 28,038 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $547,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in RXRX. Hsbc Holdings PLC grew its position in Recursion Pharmaceuticals by 26.0% during the second quarter. Hsbc Holdings PLC now owns 27,972 shares of the company’s stock worth $206,000 after buying an additional 5,764 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Recursion Pharmaceuticals by 32.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company’s stock worth $837,000 after purchasing an additional 27,440 shares in the last quarter. Algert Global LLC bought a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $129,000. SG Americas Securities LLC raised its stake in shares of Recursion Pharmaceuticals by 249.0% in the third quarter. SG Americas Securities LLC now owns 89,325 shares of the company’s stock valued at $589,000 after purchasing an additional 63,727 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Recursion Pharmaceuticals by 33.4% in the third quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company’s stock worth $458,000 after purchasing an additional 17,400 shares during the period. Institutional investors own 89.06% of the company’s stock.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the transaction, the director now owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This trade represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Down 5.9 %

Shares of NASDAQ:RXRX opened at $7.24 on Monday. The company’s fifty day moving average is $7.03 and its 200-day moving average is $6.91. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $15.74. The company has a market capitalization of $2.83 billion, a PE ratio of -4.73 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the firm earned ($0.43) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

RXRX has been the topic of several analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.